目的 研究癫痫康胶囊联合丙戊酸钠缓释片治疗癫痫的临床疗效。方法 选取2017年10月—2018年10月湖北省第三人民医院诊治的癫痫患者100例作为研究对象，采用随机对照表法将所有患者分为对照组和治疗组，每组各50例。对照组患者口服丙戊酸钠缓释片，3片/次，3次/d；治疗组在对照组治疗的基础上口服癫痫康胶囊，3粒/次，3次/d。两组患者持续治疗2个月。观察两组患者的临床疗效，同时比较两组治疗前后的医院焦虑抑郁量表（HADS）评分、癫痫放电和发作次数、血清肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）、神经元特异性烯醇化酶（NSE）和S100β蛋白（S100β）水平。结果 治疗后，对照组和治疗组的总有效率分别为82.00%、96.00%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者HAD评分、癫痫放电和发作次数均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05），且治疗后治疗组的HAD评分、癫痫放电和发作次数显著低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者TNF-α、IL-6、NSE和S100β水平均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后治疗组上述指标显著低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 癫痫康胶囊联合丙戊酸钠缓释片治疗癫痫具有较好的临床疗效，能够改善患者临床症状，降低炎性因子水平，且安全性较高，具有一定的临床推广应用价值。

Objective To study the clinical effect of Dianxiankang Capsules combined with Sodium Valproate Sustained Release Tablets in treatment of epilepsy. Methods Patients (100 cases) with epilepsy in Third People's Hospital of Hubei Province from October 2017 to October 2018 were randomly divided into control and treatment groups, and each group had 50 cases. Patients in the control group were po administered with Sodium Valproate Sustained Release Tablets, 3 tablets/time, three times daily. Patients in the treatment group were po administered with Dianxiankang Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacy was evaluated, and the HADS scores, the number of epileptic discharge and epileptic attack, and the levels of TNF-α, IL-6, NSE, and S100β in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 82.00% and 96.00%, respectively, and there were differences between two groups (P < 0.05). After treatment, HADS scores and the number of epileptic discharge and epileptic attack in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the HADS scores and the number of epileptic discharge and epileptic attack in the treatment group after treatment were significantly lower than those in the control group, with significant difference between two groups (P< 0.05). After treatment, the levels of TNF-α, IL-6, NSE, and S100β in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And those indexes in the treatment group after treatment were significantly lower than those in the control group, with significant difference between two groups (P< 0.05). Conclusion Dianxiankang Capsules combined with Sodium Valproate Sustained Release Tablets has a good clinical effect in treatment of epilepsy, can improve the clinical efficacy of patients, reduced inflammatory factor level, with high safety, which has a certain clinical application value.